Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD(TM) 2025 International Conference

Stock Information for Vigil Neuroscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vigil Neuroscience Inc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, CHTR, VIGL on Behalf of Shareholders
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR, TASK, VIGL, STRM on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRKN, ELEV, STR, VIGL on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.